Turn Therapeutics (TTRX) Current Deferred Revenue (2024 - 2025)
Turn Therapeutics' (TTRX) quarterly Current Deferred Revenue came in at $1.4 million in Q4 2025, little changed year-on-year from $1.4 million in Q4 2024, and little changed quarter-over-quarter from $1.4 million in Q3 2025.
Turn Therapeutics (TTRX) Current Deferred Revenue (2024 - 2025) Analysis & Trends
Turn Therapeutics' Current Deferred Revenue history runs 2 years deep, the most recent figure standing at $1.4 million for Q4 2025.
- On a quarterly basis, Current Deferred Revenue changed 0.0% year-over-year to $1.4 million in Q4 2025; TTM through Dec 2025 was $1.4 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $1.4 million, changed 0.0% from the prior year.
- Current Deferred Revenue steadied at $1.4 million in Q4 2025 per TTRX's latest filing, from $1.4 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $1.4 million in Q4 2024 and bottomed at $1.4 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Turn Therapeutics | 282.39 Mn | 282.39 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.44 Mn |
| Sep 30, 2025 | 1.44 Mn |
| Dec 31, 2024 | 1.44 Mn |